Newsroom | 39244 results

CANTON, Mass.--(BUSINESS WIRE)--It is with profound sadness that we announce the passing of MEDITECH Founder and Chairman, A. Neil Pappalardo, on January 27, 2026 at the age of 83. After founding the company on August 4, 1969, Mr. Pappalardo remained a guiding force and driving inspiration until his passing, establishing a legacy that spans over five decades. Pappalardo is widely credited as the founder of the Electronic Health Record (EHR) industry. His engineering background, which includes c...

DUBLIN--(BUSINESS WIRE)--The "World Market for Oncology Imaging AI, 2023-2032" report has been added to ResearchAndMarkets.com's offering. Oncology is where medical imaging AI is being tested most aggressively - and where it is starting to stick. Breast and lung screening programs, complex CT/MRI staging, PET-based theranostics, and RT planning are all pushing clinicians toward faster, more consistent, more quantitative imaging decisions. This report quantifies and explains that shift. It analy...

LEXINGTON, Mass.--(BUSINESS WIRE)--CBSET, a leading provider of translational research and product development services for the medical device, pharmaceutical, diagnostic, and biomedical research industries, is excited to announce the hiring of Michael C. John as Chief Regulatory and Innovation Officer (CRIO). A New Regulatory Consulting Business and Expanded Service Offerings In this new, dual role, Michael will be responsible for the development of a new Regulatory Consulting Business Unit th...

HAWTHORNE, Calif.--(BUSINESS WIRE)--OSI Systems, Inc. (the “Company” or “OSI Systems”) (NASDAQ: OSIS) today announced its financial results for the second quarter of fiscal 2026. Ajay Mehra, OSI Systems’ President and Chief Executive Officer, stated, “We are pleased to report record second quarter revenues and non-GAAP earnings per share, driven by strong year-over-year growth from our industry leading Security and Optoelectronics and Manufacturing divisions. Looking ahead, we expect our signif...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Announces Financial Results for First Quarter of Fiscal 2026...

JERSEY CITY, N.J.--(BUSINESS WIRE)--A Organon (NYSE: OGN), uma empresa global de saúde com a missão de fornecer medicamentos e soluções impactantes para um dia a dia mais saudável, anunciou hoje a conclusão bem-sucedida da venda de seu Sistema JADA ® para a Laborie Medical Technologies Corp. Consulte nosso comunicado anterior para obter um resumo dos termos da transação. Indicações de Uso O Sistema JADA® destina-se ao controle e tratamento de sangramento ou hemorragia uterina anormal no pós-par...

JERSEY CITY, New Jersey--(BUSINESS WIRE)--Organon (NYSE : OGN), une entreprise mondiale de soins de santé dont la mission est de fournir des médicaments et des solutions efficaces offrant une meilleure santé au quotidien, a annoncé aujourd'hui la conclusion de la vente de son système JADA ® à Laborie Medical Technologies Corp. Veuillez consulter notre annonce précédente pour lire un résumé des conditions de la transaction. Mode d'emploi Le système JADA® System vise à assurer le contrôle et le t...

JERSEY CITY, Nueva Jersey--(BUSINESS WIRE)--Organon (NYSE: OGN), una compañía global de atención de la salud orientada a ofrecer medicamentos y soluciones de impacto para una vida cotidiana más saludable, anunció hoy el cierre exitoso de la venta de su sistema JADA® a Laborie Medical Technologies Corp. Para un resumen de los términos de la transacción, consulte nuestro anuncio previo. Indicaciones de uso El sistema JADA® está indicado para proporcionar control y tratamiento del sangrado uterino...

JERSEY CITY, New Jersey--(BUSINESS WIRE)--Organon (NYSE: OGN), azienda di livello globale nel settore sanitario che offre farmaci e soluzioni d’impatto volte a migliorare la salute quotidiana, oggi ha annunciato la conclusione positiva della cessione del suo sistema JADA® a Laborie Medical Technologies Corp. Si prega di consultare il nostro precedente annuncio per una sintesi dei termini dell’operazione. Indicazioni per l’uso Il sistema JADA® è destinato al controllo e al trattamento dell’emorr...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), een wereldwijd opererend bedrijf in de gezondheidszorg met als missie het leveren van impactvolle geneesmiddelen en oplossingen voor een gezonder leven, heeft vandaag bekendgemaakt dat de verkoop van zijn JADA® -systeem aan Laborie Medical Technologies Corp. succesvol is afgerond. Zie onze eerdere aankondiging voor een samenvatting van de transactievoorwaarden. Indicaties voor gebruik Het JADA®-systeem is geïndiceerd voor de beheersing en...